Treatment of lower urinary tract infection in pregnancy
| Autor: | J. Hromec, S. Krcmery, D. Demesova |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Microbiology (medical)
Adult medicine.medical_specialty Bacteriuria Anti-Infective Agents Urinary Penicillins Fosfomycin urologic and male genital diseases Pregnancy Risk Factors Internal medicine Prevalence Medicine Humans Pharmacology (medical) Acute Cystitis Ceftibuten Pregnancy Complications Infectious Antibacterial agent business.industry Enterobacteriaceae Infections General Medicine Staphylococcal Infections medicine.disease Pyuria Surgery Cephalosporins Infectious Diseases Chemoprophylaxis Female medicine.symptom business medicine.drug |
| Zdroj: | International journal of antimicrobial agents. 17(4) |
| ISSN: | 0924-8579 |
| Popis: | Urinary tract infection (UTI) is a common complication of pregnancy. Approximately 20–40% of women with asymptomatic bacteriuria will develop pyelonephritis during pregnancy. All pregnant women, therefore, should have their urine cultured at their first visit to the clinic. In a clinical study comparing single-dose treatment with 3 g fosfomycin trometamol versus a 3-day course of 400 mg ceftibuten orally, the inclusion criteria were acute symptomatic lower UTI (acute cystitis), significant bacteriuria (≥10 3 CFU/ml), pyuria and confirmed pregnancy. Excluded were patients with asymptomatic bacteriuria or acute pyelonephritis. Predisposing factors comprised a history of recurrent UTI, diabetes mellitus, analgesic nephropathy, hyperuricaemia or Fanconi's syndrome. Escherichia coli was the most frequently isolated pathogen in both groups. Therapeutic success (clinical cure and bacteriological eradication of uropathogens) was achieved in 95.2% of the patients treated with fosfomycin-trometamol versus 90.0% of those treated with ceftibuten ( P , non-significant). The treatment of acute cystitis in pregnant women using a single-dose of fosfomycin trometamol was equally effective as the 3-day course of oral ceftibuten. Both regimens were well tolerated with only minor adverse effects. Long-term chemoprophylaxis should be suggested in patients with recurrent UTI or following acute pyelonephritis during pregnancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect